Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate DatabaseBenjamin Rolles, Valeria Santini, Mikkael A. Sekeres et al.|Blood|2024Cited by 5
Clinical Implications of <i>TP53</i> Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate DatabaseTariq Kewan, Amer M. Zeidan, Jan Philipp Bewersdorf et al.|Blood|2023Cited by 1
Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular DataTariq Kewan, Amer M. Zeidan, Jan Philipp Bewersdorf et al.|Blood|2023Cited by 1
Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate DatabaseTed M. Getz, Aref Al‐Kali, Tariq Kewan et al.|Blood|2024Cited by 0